ZA9710071B - Pharmaceutical composition. - Google Patents

Pharmaceutical composition.

Info

Publication number
ZA9710071B
ZA9710071B ZA9710071A ZA9710071A ZA9710071B ZA 9710071 B ZA9710071 B ZA 9710071B ZA 9710071 A ZA9710071 A ZA 9710071A ZA 9710071 A ZA9710071 A ZA 9710071A ZA 9710071 B ZA9710071 B ZA 9710071B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
ZA9710071A
Other languages
English (en)
Inventor
John Lipari
Laman A Al-Razzak
Soumojeet Ghosh
Rong Gao
Dilip Kaul
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25034589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9710071(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ZA9710071B publication Critical patent/ZA9710071B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ZA9710071A 1996-11-21 1997-11-07 Pharmaceutical composition. ZA9710071B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75439096A 1996-11-21 1996-11-21

Publications (1)

Publication Number Publication Date
ZA9710071B true ZA9710071B (en) 1998-05-25

Family

ID=25034589

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9710071A ZA9710071B (en) 1996-11-21 1997-11-07 Pharmaceutical composition.

Country Status (26)

Country Link
EP (2) EP1283041A1 (es)
JP (2) JP3592337B2 (es)
KR (2) KR100478075B1 (es)
CN (3) CN1989963B (es)
AR (2) AR010634A1 (es)
AT (1) ATE231393T1 (es)
AU (1) AU717546B2 (es)
BG (1) BG64411B1 (es)
BR (1) BR9714310A (es)
CA (2) CA2505430A1 (es)
CZ (1) CZ299728B6 (es)
DE (1) DE69718668T2 (es)
DK (1) DK0942721T3 (es)
ES (1) ES2191862T3 (es)
HK (1) HK1053787A1 (es)
HU (1) HU224319B1 (es)
IL (1) IL129300A (es)
NO (1) NO326927B1 (es)
NZ (1) NZ335002A (es)
PL (1) PL190185B1 (es)
PT (1) PT942721E (es)
SK (1) SK285022B6 (es)
TR (1) TR199901129T2 (es)
TW (1) TW475895B (es)
WO (1) WO1998022106A1 (es)
ZA (1) ZA9710071B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
DE69808463T2 (de) * 1997-07-29 2003-06-26 Pharmacia & Upjohn Co., Kalamazoo Selbstemulgierende formulierung enthaltend saure lipophile verbindungen
ATE215370T1 (de) * 1997-07-29 2002-04-15 Upjohn Co Selbstemulgierende formulierung enthaltend lipophile verbindungen
DE69823663T2 (de) * 1997-07-29 2005-05-19 Pharmacia & Upjohn Co., Kalamazoo Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
JP2002528502A (ja) * 1998-11-04 2002-09-03 ファルマシア・アンド・アップジョン・カンパニー チプラナビルの薬物動態を改善する方法
EP1712231A3 (en) * 1998-11-04 2007-11-21 Pharmacia & Upjohn Company LLC Method for improving the pharmacokinetics of tipranavir
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
TR200103488T2 (tr) * 1999-06-04 2002-04-22 Abbott Laboratories Geliştirilmiş farmasötik formülasyonlar.
JP5767429B2 (ja) 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
WO2001041742A2 (en) * 1999-12-09 2001-06-14 Alza Corporation Antiviral medication
CA2395987C (en) * 2000-01-19 2009-12-22 Abbott Laboratories Improved pharmaceutical formulations
AU2001259817A1 (en) * 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
US6911214B2 (en) 2000-09-05 2005-06-28 Abbott Laboratories Flavoring systems for pharmaceutical compositions and methods of making such compositions
EP1395249A1 (en) * 2001-05-25 2004-03-10 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
BR0202252A (pt) * 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
BR0302424A (pt) * 2003-07-23 2005-03-29 Cristalia Prod Quimicos Farm Composição farmacêutica com biodisponibilidade ampliada adequada à adiministração oral de inibidores da protease retroviral. processo de preparação de composição farmacêutica concentrada contendo inibidor da protease retroviral
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
KR101229431B1 (ko) * 2004-07-06 2013-02-04 아보트 러보러터리즈 Ｈｉｖ 프로테아제 억제제의 프로드럭
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
EP2714683A4 (en) 2011-05-27 2014-11-05 Hetero Research Foundation RITONAVIR AMORPH CO-PRECIPITATION
US20150086628A1 (en) 2012-05-03 2015-03-26 Cipla Limited Antiretroviral composition
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0558603B1 (en) * 1990-11-19 1998-08-26 Monsanto Company Retroviral protease inhibitors
ATE216371T1 (de) * 1991-10-11 2002-05-15 Du Pont Pharm Co Cyclische harnstoffe und analoga verwendbar als retrovirale proteasehemmer
DK0541168T3 (da) * 1991-11-08 1998-05-11 Merck & Co Inc HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
CA2131182C (en) * 1992-05-20 2005-04-26 John S. Ng Method for making intermediates useful in synthesis of retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
DK0727419T3 (da) * 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5646180A (en) * 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
ES2191862T3 (es) 2003-09-16
PT942721E (pt) 2003-06-30
IL129300A (en) 2003-07-06
DK0942721T3 (da) 2003-05-19
SK285022B6 (sk) 2006-04-06
TR199901129T2 (xx) 2001-05-21
EP1283041A1 (en) 2003-02-12
HU224319B1 (hu) 2005-07-28
AR048891A2 (es) 2006-06-07
CN1248914A (zh) 2000-03-29
SK65599A3 (en) 1999-12-10
JP4523799B2 (ja) 2010-08-11
CN1989963B (zh) 2011-06-29
NO992427D0 (no) 1999-05-20
BG64411B1 (bg) 2005-01-31
CA2271196A1 (en) 1998-05-28
CN1989963A (zh) 2007-07-04
CA2505430A1 (en) 1998-05-28
JP2004346077A (ja) 2004-12-09
KR20000057169A (ko) 2000-09-15
IL129300A0 (en) 2000-02-17
CZ160299A3 (cs) 1999-08-11
AU5257398A (en) 1998-06-10
NZ335002A (en) 2001-08-31
NO992427L (no) 1999-07-20
HK1053787A1 (zh) 2003-11-07
JP3592337B2 (ja) 2004-11-24
KR20040004426A (ko) 2004-01-13
AR010634A1 (es) 2000-06-28
DE69718668D1 (de) 2003-02-27
CN1250219C (zh) 2006-04-12
KR100516567B1 (ko) 2005-09-22
CZ299728B6 (cs) 2008-11-05
NO326927B1 (no) 2009-03-16
EP0942721B1 (en) 2003-01-22
EP0942721A1 (en) 1999-09-22
PL336980A1 (en) 2000-07-31
KR100478075B1 (ko) 2005-03-23
ATE231393T1 (de) 2003-02-15
JP2000515555A (ja) 2000-11-21
PL190185B1 (pl) 2005-11-30
BG103425A (en) 2000-04-28
HUP0002932A2 (hu) 2001-01-29
BR9714310A (pt) 2000-05-02
CA2271196C (en) 2005-06-28
WO1998022106A1 (en) 1998-05-28
CN101103984A (zh) 2008-01-16
HUP0002932A3 (en) 2001-03-28
DE69718668T2 (de) 2003-10-02
AU717546B2 (en) 2000-03-30
TW475895B (en) 2002-02-11

Similar Documents

Publication Publication Date Title
ZA9710071B (en) Pharmaceutical composition.
ZA9710927B (en) Pharmaceutical composition.
ZA965190B (en) Pharmaceutical composition.
ZA975947B (en) Aqueous-based pharmaceutical composition.
HK1027957A1 (en) Pharmaceutical composition.
ZA974735B (en) Pharmaceutical compositions.
ZA9711508B (en) Rapidly disintegrable pharmaceutical composition.
ZA975533B (en) Cyclosporin-containing pharmaceutical composition.
ZA978178B (en) Composition.
ZA967034B (en) Pharmaceutical compositions.
ZA975261B (en) Composition.
ZA9811504B (en) Novel pharmaceutical.
ZA977104B (en) Pharmaceutical compositions.
ZA200005510B (en) Pharmaceutical composition.
ZA989680B (en) Pharmaceutical composition.
ZA9710272B (en) Pharmaceutical compositions comprising diaryl-cyclomethylenpyrazole compounds.
ZA9811506B (en) Novel pharmaceutical.
ZA968081B (en) Pharmaceutical composition.
ZA9811505B (en) Novel pharmaceutical.
GB9610359D0 (en) Pharmaceutical compositions
HK1022853A1 (en) Pharmaceutical compositions.
ZA987392B (en) Pharmaceutical composition.
ZA972602B (en) Pharmaceutical compositions.
HK1044117A1 (en) Pharmaceutical composition.
GB9613457D0 (en) Pharmaceutical compositions